Working… Menu

Plasma Levels of Matrix Metalloproteinases (MMPs) and Degree of DNA Fragmentation in Pseudoexfoliation (PEX) Glaucoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00327613
Recruitment Status : Completed
First Posted : May 18, 2006
Last Update Posted : September 26, 2008
Information provided by:
University Hospital, Basel, Switzerland

Brief Summary:

Glaucoma is a worldwide leading cause of blindness. The key feature of this ocular neuropathy is characterized by an excavating optic nerve head. Loss of retinal ganglion cells is the final end point in blinding diseases of the optic nerve such as glaucoma. It is known that neuronal cell death in glaucoma occurs by apoptotic mechanism. In earlier studies, the investigators demonstrated that the process of apoptosis is reflected in circulating leukocytes by different parameters, like differential messenger ribonucleic acid (mRNA) expression and an increased fragmentation of the deoxyribonucleic acid (DNA). Such alterations point out a relationship between cellular stress and apoptotic events.

Based on the results of mRNA-expression, the investigators also expect alterations on the protein level.

This study is, therefore, designed to characterize the proteome related to the proteins involved in cell death related pathways.

Thus the expression pattern of several proteins in leukocytes from patients with primary open angle glaucoma will be analyzed by techniques like Western-blot and tandem mass spectrometry. These samples will be compared with healthy controls. In addition, they will be also compared with samples from patients with Parkinson's disease. Since glaucoma is a neurodegenerative disease, these patients will be included as a positive control in this study.

Condition or disease
Pseudoexfoliation Syndrome Glaucoma

  Show Detailed Description

Layout table for study information
Study Type : Observational
Actual Enrollment : 60 participants
Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Plasma Levels of Matrix Metalloproteinases and Degree of DNA Fragmentation in Patients With Pseudoexfoliation Syndrome and Open-Angle Glaucoma (PEXG)
Study Start Date : June 2005
Actual Primary Completion Date : April 2008
Actual Study Completion Date : April 2008

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Glaucoma

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients with pseudoexfoliation

Inclusion Criteria:

  • German native speakers
  • Age between 18-80 years
  • Pseudoexfoliation syndrome
  • Pseudoexfoliation syndrome with open-angle glaucoma
  • Primary open-angle glaucoma

Exclusion Criteria:

  • Any history of ocular or systemic diseases other than glaucoma or of drug or alcohol abuse.
  • Any condition potentially interfering with the visual field results. Visual fields will be obtained from the chart.
  • Any mentally impaired patient.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00327613

Layout table for location information
University Eye Clinic Basel
Basel, BS, Switzerland, 4031
Sponsors and Collaborators
University Hospital, Basel, Switzerland
Layout table for investigator information
Study Director: Selim Orgül, MD University Hospital, Basel, Switzerland

Layout table for additonal information
Responsible Party: Selim Orgul, University Hospital, Basel, Switzerland Identifier: NCT00327613     History of Changes
Other Study ID Numbers: 066-WUK-2005-001
First Posted: May 18, 2006    Key Record Dates
Last Update Posted: September 26, 2008
Last Verified: September 2008
Keywords provided by University Hospital, Basel, Switzerland:
DNA degradation
Healthy subjects
Additional relevant MeSH terms:
Layout table for MeSH terms
Exfoliation Syndrome
Pathologic Processes
Ocular Hypertension
Eye Diseases
Iris Diseases
Uveal Diseases